Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes mellitus (T2DM) treatment with demonstrated weight loss benefits in clinical trials. However, the extent to which real-world patients with T2DM achieve clinically meaningful weight loss (≥5%) has not been well...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Tracey, Yang, Lingfeng, Carr, Richard D, Pal, Sampriti, Sawhney, Baanie, Boggs, Robert, Rajpathak, Swapnil, Iglay, Kristy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804648/
https://www.ncbi.nlm.nih.gov/pubmed/35101924
http://dx.doi.org/10.1136/bmjdrc-2021-002517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804648/
https://www.ncbi.nlm.nih.gov/pubmed/35101924
http://dx.doi.org/10.1136/bmjdrc-2021-002517

Ejemplares similares